Please login to the form below
Tecentriq
This page shows the latest Tecentriq news and features for those working in and with pharma, biotech and healthcare.
NHS England to offer world-first seven-minute cancer treatment injection
Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%. ... NHS England will be the first health system in the world to roll out the subcutaneous formulation of Tecentriq (atezolizumab) to eligible patients, following a
Latest news
-
Roche reports positive phase 3 data for Tecentriq combination in liver cancer
The Tecentriq investigational combination reduced the risk of cancer returning by 28%, compared with active surveillance, at a median follow-up of 17.4 months. ... Safety for both Tecentriq and Avastin was reportedly consistent with the known safety
-
Genentech reports positive phase 3 data for its Tecentriq combination in liver cancer
Tecentriq in combination with Avastin significantly improved recurrence-free survival. Genentech – a member of the Roche group – has announced that its phase 3 study of Tecentriq (atezolizumab) combination mets its primary ... Safety for both
-
Roche launches digital PCR system to identify ultra-rare and emerging disease mutations
Roche’s Tecentriq is a cancer immunotherapy that has the potential to be used in combination with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. ... cancer (NSCLC) for whom prior platinum therapy
-
Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
Roche’s Tecentriq is a cancer immunotherapy that has the potential to be used in combination with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. ... In June this year, Tecentriq was approved by the
-
Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
Subcutaneously administering Tecentriq reduced the time needed for treatment compared to standard IV infusion. ... The investigational subcutaneous formulation combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.
More from news
Approximately 75 fully matching, plus 91 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
2019. The only drug that has any realistic chance of challenging Keytruda in NSCLC is Roche’s Tecentriq. ... The Tecentriq chemo trial, IMpower132, is the most important head-to-head with Keytruda (in non-squamous NSCLC).
-
The handover: Pfizer reshapes itself for a new era
The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it
-
Cancer immunotherapy: What's on the horizon?
It’s not all been plain sailing, with BMS’ Opdivo (nivolumab) and Roche’s Tecentriq not doing as well as hoped in frontline NSCLC, revealing there are differences between checkpoint inhibitors – ... The drugmaker thinks Avastin may enhance
-
Europe vs the US: New drug product approvals
Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
